Lymphatic drainage of the breast
42 min
- Improving on "Natural" Rodent Antibodies
-
26 min
1. The immunogenicity problem in antibody therapy- Prof. Herman Waldmann
-
32 min
2. Antibodies by protein engineering- Prof. Sir Gregory Winter
-
60 min
3. The generation of diversity in antibody genes- Prof. Michael Neuberger
-
51 min
4. Innate immunity to retroelements by human AID/APOBEC3 proteins- Prof. Reuben Harris
-
36 min
5. Fc receptors and antibody effector functions- Dr. Mike Clark
-
57 min
6. Antibody engineering of Fc effector functions- Dr. Mike Clark
-
35 min
7. Antibody engineering: beginnings to bispecifics and beyond- Dr. Ian Wilkinson
- Antibodies in Cancer Therapy
-
41 min
8. Monoclonal antibodies and the ErbB system in human cancer- Prof. Mark Greene
-
71 min
9. Checkpoint blockade in cancer immunotherapy- Prof. James Allison
-
45 min
10. Monoclonal antibodies in haemato-oncology- Prof. Mark Cragg
- Diagnostic Antibodies
-
46 min
11. Monitoring therapy with antibodies- Dr. Geoffrey Hale
- Cell Surface Glycoproteins on Cells of the Immune System
-
38 min
12. Cell surface glycoproteins on cells of the immune system- Prof. Neil Barclay
- Antibodies as Immunosuppressants
-
29 min
13. Monoclonal antibodies to induce therapeutic immunological tolerance- Prof. Herman Waldmann
-
29 min
14. Antibodies to control or prevent type 1 diabetes- Dr. Robert Hilbrands
-
48 min
15. Antibody therapy of multiple sclerosis- Dr. Alasdair Coles
- Prof. Alastair Compston
-
42 min
16. Monoclonal antibodies in the management of rheumatoid arthritis- Prof. John Isaacs
-
40 min
-
30 min
- Archived Lectures *These may not cover the latest advances in the field
-
26 min
19. Alemtuzumab (Campath-1H) in therapy of CLL- Prof. Kanti Rai
-
71 min
20. VEGF inhibitors for anti-angiogenic therapy- Prof. Kari Alitalo
- Dr. Bronislaw Pytowski
-
26 min
21. Human antibodies produced in mice- Dr. Marianne Bruggemann
-
52 min
22. New strategies to prevent transplant rejection: from molecules to mice to monkeys to man- Prof. Christian Larsen
-
55 min
23. CD20 antibodies in the targeting of B-cell malignancies and autoimmunity- Prof. Thomas Tedder
-
45 min
24. Anti-IL-2 receptor antibodies as models for cancer therapy- Prof. Thomas Waldmann
-
58 min
25. Anti TNF therapy in rheumatoid arthritis- Prof. Marc Feldmann
-
36 min
26. Novel immunotherapeutic proteins: immunoligand- Prof. Terry Strom
-
21 min
27. Diagnostic immunohistopathology- Prof. David Mason
-
56 min
28. Antibodies in the control of type I diabetes- Prof. Lucienne Chatenoud
-
43 min
29. The challenge of targeting toxins to tumors- Prof. Ben Seon
-
38 min
30. Antibody depletion therapy in transplantation: implications for tolerance- Prof. Laurence Turka
-
36 min
31. Antibodies as anti-virals- Prof. Dennis Burton
Printable Handouts
Navigable Slide Index
- Introduction
- Angiogenesis-VEGF
- Angiogenesis-VEGF-C/D
- VEGF and VEGFR tyrosine kinase
- Strategies to inhibit VEGFR signaling
- MuMAb VEGF A4.6.1
- RhuMAb VEGF-Avastin
- Blocking Ab differ from other agents
- Anti-VEGF Ab prevents VEGF/VEGFR interaction
- Potential effects of inhibiting VEGF
- Anti-angiogenesis 'normalises' tumour vasculature
- Anti-VEGF Ab modifies tumor vasculature
- VEGF inhibition can induce capillary regression
- Ranibizumab
- Pegaptanib
- 'Metronomic' anti-angiogenic chemotherapy
- Preclinical models
- Potential effects of anti-VEGF therapy
- Anti-VEGFR2 mAb
- Treatment of human xenograft tumors with DC101
- VEGFR-2 blockade
- VEGFR-2 block leads to increase in tumor hypoxia
- Anti-VEGFR-2 mAb and gemcitabine
- VEGFR-2 Ab IMC-1121b
- Structure and properties of VEGF trap
- Angiogenesis inhibitors in clinical trials
- Conclusions (1)
- Conclusions (2)
- Inhibitors of lymphangiogenesis
- Tumor lymphangiogenesis and metastasis
- VEGF-C/D trap prevents VEGFR-3 signaling
- VEGF-C/D trap prevents lymph vessels growth
- Inhibition of lymphangiogenesis with VEGFR-3-Fc
- Blocking metastasis to lymph nodes
- Model of lymphatic metastasis
- Model of prevention of lymphatic metastasis
- Proteolytic processing of VEGF-C/D
- VEGF in hematogenous and lymphatic spread
- Antagonist monoclonal Abs to VEGFR-3
- Soluble receptors (traps) and antagonist antibodies
- Antagonist monoclonal antibodies to VEGFR-3
- Mode of action of antagonist mAbs to RTKs
- Functional properties of alpha-VEGFR-3 mAbs
- Dermal lymphatic regeneration model in mouse
- Systemic alpha-VEGFR-3 treatment
- Angio- and lymphangiogenesis blocking
- Alpha-VEGFR-3 inhibits growth of carcinomas
- Alpha-VEGFR-3 inhibits metastasis of carcinoma
- VEGF-C induces hypertrophy of lymphatic vessels
- Alpha-VEGFR-3 inhibits lymph vessels hypertrophy
- Alpha-VEGFR-3 reduces metastasis to lymph
- The role of VEGFR-3 in inflammation
- Expansion of the lymphatic network
- Prevention of lymphatic hyperplasia
- Alpha-VEGFR-3 modulates adaptive immunity
- VEGF-C, VEGFR-3 and inflammation (1)
- VEGF-C, VEGFR-3 and inflammation (2)
- Rejection of renal transplants
- Conclusions (3)
Topics Covered
- Antagonist monoclonal antibodies to VEGFR-3
- Mode of action of antagonist monoclonal antibodies
- Functional properties of antagonist antibodies to VEGFR-3
- In vivo effects of anti-VEGFR-3 treatment on physiological lymphangiogenesis
- Inhibition of pathological vessel growth in the cornea
- Anti-angiogenic effect of antibodies to VEGFR-3 in tumors
- Inhibition of lymphatic metastasis with antagonist antibodies to VEGFR-3
- Role of VEGFR-3 in normal and pathological immune response
Links
Series:
Categories:
Therapeutic Areas:
Talk Citation
Alitalo, K. and Pytowski, B. (2007, October 1). VEGF inhibitors for anti-angiogenic therapy [Video file]. In The Biomedical & Life Sciences Collection, Henry Stewart Talks. Retrieved February 5, 2025, from https://doi.org/10.69645/SSHQ8214.Export Citation (RIS)
Publication History
Financial Disclosures
- Prof. Kari Alitalo has not informed HSTalks of any commercial/financial relationship that it is appropriate to disclose.
- Dr. Bronislaw Pytowski has not informed HSTalks of any commercial/financial relationship that it is appropriate to disclose.
